Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? (Q41084671)

26 September 2017

1 reference

title

Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? (English)

1 reference

26 September 2017

Mani S

1

1 reference

26 September 2017

Vogelzang NJ

series ordinal

2

1 reference

26 September 2017

publication date

1 June 1996

1 reference

Hematology / Oncology Clinics of North America

26 September 2017

published in

1 reference

26 September 2017

volume

10

1 reference

26 September 2017

issue

3

1 reference

26 September 2017

page(s)

749-768

1 reference

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Carboplatin in advanced hormone refractory prostatic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

The chemotherapy of urologic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin and prostate cancer: where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Oral cyclophosphamide for the management of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970365-8

7 January 2021

10.1016/S0889-8588(05)70365-8

Identifiers

DOI

1 reference

26 September 2017

1 reference